anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

232,381-232,440 of 319,975

filter-aware
29
Forest plot showing hazard ratios with 95% confidence intervals for multiple clinical subgroups.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
30
The table compares safety data across various categories of adverse events, including grade 3/4, serious AEs, and treatment-related outcomes.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
31
The chart uses a diverging bar structure to compare two treatment arms side-by-side.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
32
AstraZeneca | Investor Event Presentation Deck | 55 slidesAstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
33
Includes corporate branding and a biological illustration of an antibody-drug conjugate or similar protein structure.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
34
The slide uses a market segmentation approach to map clinical trials (NIAGARA, POTOMAC, VOLGA, NILE) to patient populations (NMIBC, MIBC, 1L mUC).AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
35
The slide uses a three-row structure to categorize reasons for confidence: clinical evidence, safety/experience, and implementation/stakeholder alignment.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
36
Slide lists 6 internal leaders and 1 external expert.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
37
The slide features a 3D rendering of an antibody molecule.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
38
The chart is a stacked area chart showing market growth by target segment (HER2, TROP2, Nectin4, etc.).AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
39
The slide uses a horizontal bar chart to represent clinical development stages for six different ADC assets.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
40
The slide compares plasma concentration over time for two different ADCs, showing the stability of the ADC vs the mAb and the low levels of free payload.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
41
Waterfall plot shows best change in target lesion size; includes CA-125 response markers.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
42
Waterfall plot shows RECIST v1.1 response criteria. Includes legend for dose levels and callout boxes for clinical outcomes.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
43
The slide features a stylized 3D rendering of a bispecific antibody molecule.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
44
The slide highlights the structural design (knob-into-hole) and clinical development pipeline for two specific IO assets.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
45
WCLC conference presentation slide. Includes waterfall plot and summary table of ORR and treatment continuation.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
46
Spider plot (swimmer plot variant) showing individual patient response trajectories.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
47
Waterfall plot shows tumor shrinkage; includes key clinical metrics (ORR, mPFS) and safety/future trial status.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
48
AstraZeneca | Investor Event Presentation Deck | 55 slidesAstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
49
The chart uses a bridge/waterfall structure to show revenue growth drivers.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
50
The slide uses a grid-based layout to organize events by year, with checkmarks indicating completed or high-priority milestones.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
51
The slide lists six key executives with their titles and headshots.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
52
AstraZeneca | Investor Event Presentation Deck | 55 slidesAstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
53
The slide uses a grid layout to categorize clinical trials by disease stage and patient population, highlighting established standards of care (SoC) with hatched patterns.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
54
The slide uses a matrix structure to categorize clinical trials (e.g., DESTINY-Breast, TROPION-Breast, CAPItello) by patient population and treatment line.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
55
AstraZeneca | Investor Event Presentation Deck | 55 slidesAstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
01
Slide 1
BenevolentAI | Investor Presentation Deck | 31 slidesBenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
02
BenevolentAI | Investor Presentation Deck | 31 slidesBenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
03
The slide uses a non-linear, interconnected circular node design to represent a timeline.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
04
The slide combines team bios with business model and partnership validation.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
05
Uses a structured layout to categorize problems into three pillars: cost/risk, time, and efficacy.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
06
BenevolentAI | Investor Presentation Deck | 31 slidesBenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
07
The slide uses a split-screen layout to contrast partnership-based revenue with internal pipeline development.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
08
The slide uses a process flow diagram to illustrate the drug discovery pipeline.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
09
The slide uses a circular arrow graphic to represent a feedback loop between in-silico and in-vitro processes.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
10
The slide uses a 'How we did it' process flow at the bottom to explain the underlying methodology.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
11
The slide uses a timeline on the left and a summary of partnership terms on the right.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
12
BenevolentAI | Investor Presentation Deck | 31 slidesBenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
13
The slide uses a Gantt-style chart to show the progress of different drug programs. It distinguishes between proprietary (teal) and partner (yellow) pipelines.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
14
Includes two process diagrams illustrating the Benevolent Platform's role and the experimental validation process.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
15
The slide uses a table to demonstrate market validation for early-stage IBD assets.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations Beat · Market Size1 hit
16
The slide uses a causal chain logic to connect market deal activity and clinical unmet needs to the value proposition of the drug.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations Loop · Why Now1 hit
17
The slide uses a two-row structure to contrast 'Collaborations' and 'Out licensing' business models.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
18
The slide uses a grid layout to present three distinct partner endorsements with associated logos and investment figures.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
19
The slide uses a grid layout to present financial KPIs.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations Beat · Financials1 hit
20
The slide uses a vertical list format to present the investment thesis.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
21
BenevolentAI | Investor Presentation Deck | 31 slidesBenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
22
Includes corporate structure details, shareholder list, and headshots of leadership.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
23
Includes a reference to Eroom's law, which describes the observation that drug discovery is becoming slower and more expensive over time.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations Beat · Agitate (Make it worse)1 hit
24
The slide uses a split-screen approach to contrast two distinct value drivers: cost reduction and success rate improvement.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
25
The slide uses a table format to demonstrate differentiation and market potential for five specific pipeline assets.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
26
The slide outlines a standard clinical trial structure (SAD, Food Effect, MAD) and highlights the competitive advantage of a clean safety profile compared to historical PDE10 inhibitors.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
27
The slide emphasizes the absence of CNS-associated adverse events, which is a key differentiator for this PDE10 inhibitor.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
28
The slide uses a combination of text, scientific charts (dose-response curves), and a process diagram to validate the drug's mechanism.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
29
The slide uses a honeycomb/network diagram to represent data integration and processing.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
30
The slide uses a process flow diagram to map specific technical capabilities to stages of drug discovery.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
31
The slide uses a three-column layout to categorize value drivers: proprietary pipeline, partnerships, and future growth.BenevolentAI | Investor Presentation Deck | 31 slides · BenevolentAI
Pitch deck Investor relations 1 hit
01
Slide 1
Delivery Hero | Investor Presentation Deck | 54 slidesDelivery Hero | Investor Presentation Deck | 54 slides · Delivery Hero
Conference presentation Investor relations 1 hit
02
Delivery Hero | Investor Presentation Deck | 54 slidesDelivery Hero | Investor Presentation Deck | 54 slides · Delivery Hero
Conference presentation Investor relations 1 hit